DEA Buprenorphine Telemedicine Rule: What OUD Providers Need to Know
Yes, this rule is permanent, and it’s separate from the temporary extension everyone’s watching expire in December. If you treat opioid use disorder via telemedicine, this is the rule that’s actually built around your patients specifically, not the broader one covering all controlled substances.
What Does This Rule Actually Let OUD Providers Do?
Under the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule (90 FR 6504, effective December 31, 2025), a DEA-registered practitioner can prescribe buprenorphine for OUD via audio-only or audio-video telemedicine, for a new patient they’ve never seen in person.
The supply cap is six calendar months, split across however many prescriptions or refills make clinical sense. That’s notably longer than the 30 days DEA originally proposed. Commenters pushed back hard on 30 days, and DEA agreed it wasn’t realistic.
What Do You Have to Do Before Writing the Prescription?
Check the state PDMP where the patient is located, and write down the date and time you did it in the patient’s record. This applies every time you issue a prescription or refill under this rule, not just the first one.
If the PDMP is down or unreachable, you can still prescribe, but only a 7-day supply at a time. You’ll need to note the date and time you tried, and keep renewing that 7-day prescription (logging each attempt) until you reach the six-month cap or the PDMP comes back online.
What Happens at the Pharmacy?
The pharmacist has to verify the patient’s identity before filling the prescription, using a government-issued photo ID or another acceptable document like a utility bill, paycheck, or tribal ID. For minors or unhoused patients without standard ID, a school transcript or a shelter staff letter works too.
DEA built this in because, with no in-person visit ever required, ID verification at the pharmacy is the one consistent checkpoint confirming the person picking up the prescription is the actual patient. Worth knowing: 43 states already required something similar before this rule existed, so for most practices this isn’t a new burden, just a federal floor matching what many states already do.
What Happens After Six Months?
Once a patient hits the six-month mark under this rule with you, you’ve got two options to keep prescribing: conduct an in-person medical evaluation, or continue treatment under a different authorized telemedicine pathway. The clock is per practitioner, so if a patient changes prescribers, the six months starts over with the new one.
If you ever do conduct an in-person evaluation, the Ryan Haight telemedicine restrictions stop applying to that patient altogether, you’re no longer operating under this rule for them at all.
What Should OUD Providers Do to Stay Compliant?
- Build the PDMP-check-and-document step into every telemedicine buprenorphine encounter, including refills, not just the first prescription.
- Confirm your EHR is actually logging the date and time of each PDMP review automatically. Most modern systems do, but it’s worth checking rather than assuming.
- Track each patient’s six-month clock from their first prescription under this rule, so you’re not caught off guard when it’s time for an in-person visit or a pathway switch.
- Make sure your dispensing pharmacy knows what counts as acceptable ID under this rule, especially for patients without a standard driver’s license.
- Consult your compliance counsel.
Source
Federal Register Final Rule, January 17, 2025: Expansion of Buprenorphine Treatment via Telemedicine Encounter
This post is for educational purposes only and does not constitute legal or compliance advice. Consult a qualified attorney or compliance professional before acting on this information.
